OptimizeRx (OPRX) Receivables - Net (2010 - 2026)

OptimizeRx (OPRX) has 17 years of Receivables - Net data on file, last reported at $32.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 2.23% year-over-year to $32.0 million; the trailing twelve-month figure through Mar 2026 stood at $32.0 million (down 2.23% YoY), and the FY2025 full-year result was $37.8 million, down 1.2% from the prior year.
• Receivables - Net slipped to $32.0 million in Q1 2026, from $37.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $38.2 million in Q4 2024 to a low of $17.8 million in Q3 2022.
• A 5-year average of $27.0 million and a median of $26.3 million in 2024 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net declined 14.14% in 2022 and surged 63.77% in 2024, its largest moves.
• Tracing OPRX's Receivables - Net over 5 years: stood at $22.2 million in 2022, then surged by 63.63% to $36.3 million in 2023, then advanced by 5.4% to $38.2 million in 2024, then decreased by 1.2% to $37.8 million in 2025, then slipped by 15.27% to $32.0 million in 2026.
• Business Quant data shows OPRX's Receivables - Net at $32.0 million in Q1 2026, $37.8 million in Q4 2025, and $32.2 million in Q3 2025.